Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension

Journal of Hypertension

Volumn 27, Issue 10, 2009, Pages 1988-2000

  Bürgelová, Marcela ^a   Vaňourková, Zdenka ^b,c   Thumová, Monika ^b,c   Dvořák, Pavel ^b   Opočenský, Martin ^a   Kramer, Herbert J ^d   Zelízko, Michal ^b   Malý, Jan ^a   Bader, Michael ^e   Červenka, Luděk ^b,c,f  

^a Department of Nephrology   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c Center for Cardiovascular Research   (Czech Republic)

^d UNIVERSITY OF BONN   (Germany)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^f CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiotensin II; Angiotensin (1 7); Angiotensin converting enzyme 2; Renal function; Renin angiotensin system; Two kidney one clip Goldblatt hypertension

Indexed keywords

ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRINKING WATER; HYBRID PROTEIN; NATRIURETIC FACTOR; SODIUM CHLORIDE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; CIRCULATION; CONTROLLED STUDY; DISEASE COURSE; HEMODYNAMICS; KIDNEY FUNCTION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENOVASCULAR HYPERTENSION; TELEMETRY; TRANSGENIC MOUSE; VASODILATATION;

EID: 70350458729     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832f0d06     Document Type: Article

References (43)

1. Navar LG, Zou L, Von Thun A, Wang CT, Imig JD, Mitchell KD. Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 1998; 13:170-176.
2. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin- angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59:251-287.
3. Cervenka L, Wang CT, Mitchell KD, Navar LG. Proximal tubular angiotensin II levels and renal functional responses to AT1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats. Hypertension 1999; 33:102-107. (Pubitemid 29061849)
4. Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 2008; 585:303-312.
5. Santos RAS, Ferrerira AJ, Simoes e Silva AC. Recent advances in the angiotensin-converting enzyme2-angiotensin(1-7)-Mas axis. Exp Physiol 2008; 93:519-527.
6. Varagic J, Trask AJ, Jessup JA, Chappel MC, Ferrario CM. New angiotensins. J Mol Med 2008; 86:663-671.
7. Vickers C, Hales P, Kaushik V, Dick L, Gavin L, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277:14838-14843.
8. Jonyner J, Neves AS, Granger JP, Alexander BT, Merrill DC, Ferrario CM, et al. Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. Am J Physiol 2007; 293:R169-E177.
9. Santos RAS, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003; 100:8258-8263.
10. Burns KD. The emerging role of angiotensin-converting enzyme-2 in the kidney. Curr Opin Nephrol Hypertens 2007; 16:116-121.
11. Alenina N, Xu P, Rentzsch B, Patkin EL, Bader M. Genetically altered animal models for Mas and angiotensin-(1-7). Exp Physiol 2008; 93:528-537.
12. Bürgelová M, Kramer HJ, Teplan V, Thumová M, Cervenka L. Effects of angiotensin-(1-7) blockade on renal function in rats with enhanced intrarenal ANG II activity. Kidney Int 2005; 67:1453-1461.
13. Santos RAS, Ferreira AJ, Nadu AP, Braga AN, de Almeida AP, Campagnole-Santos MJ, et al. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 2004; 17:292-299.
14. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurements in humans and experimental animals. Part 2: Blood pressure measurements in experimental animals. Hypertension 2005; 45:299-310.
15. Whitesall SE, Hoff JB, Vollmer AP, DAlecy LG. Comparisonof simultaneous measurements of mouse systolic arterial blood pressure by radiotelemetry and tail-cuff methods. Am J Physiol 2004; 286:H2408-H2415.
16. Chin SY, Wang CT, Majid DSA, Navar LG. Renoprotective effects of nitric oxide in angiotensin II-induced hypertension in the rat. Am J Physiol 1998; 274:F876-F882.
17. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995; 269:H313-H319.
18. Widdop RE, Sampey DB, Jarrot B. Cardiovascular effects of angiotensin-(1-7) in conscious spontaneously hypertensive rats. Hypertension 1999; 34:964-968.
19. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, et al. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 2002; 124:11852-11853.
20. Husková Z, Kramer HJ, Thumová M, Van?ourková Z, Bürgelová M, Teplan V, et al. Effects of anaesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press Res 2006; 29:74-83.
21. Fox J, Guan S, Hymel AA, Navar LG. Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol 1992; 262:F902-F909.
22. Van? ourková Z, Kramer HJ, Husková Z, Vane?c?ková I, Opoc?enský O, C? ertíková Chábová V, et al. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens 2006;2465-2472.
23. Huskova Z, Kramer HJ, Van?ourková Z, Thumová M, Malý J, Opoc?enský M, et al. Effects of dietary salt load and salt depletion on the course of hypertension and angiotensin II levels in male and female heterozygous Ren-2 transgenic rats. Kidney Blood Press Res 2007; 30:45-55.
24. Cervenka L, Vanecková I, Husková Z, Van?ourková Z, Erbanová M, Thumová M, et al. Pivotal role of angiotensin II receptor subtype 1A in the development of two-kidney, one-clip hypertension: study in angiotensin II receptor subtype 1A knockout mice. J Hypertens 2008; 26:1379-1389.
25. Senanayake PS, Smeby RR, Martins AS, Moriguchi A, Kumagai H, Ganten D, et al. Adrena, kidney, and heart angiotensins in female murine Ren-2 transfected hypertensive rats. Peptides 1998; 19:1685-1694.
26. Bü rgelová M, Kramer HJ, Teplan V, Velic? ková G, V́itko S, Heller J, et al. Intrarenal infusion of angiotensin-(1-7) modulates renal functional responses to exogenous angiotensin II in the rat. Kidney Blood Press Res 2002; 25:202-210.
27. Ingelfinger JR. Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 2009; 18:79-84.
28. Rerreira AJ, Raizada MK. Genomic proteomic approaches for targeting of angiogensin-converting enzyme 2 for cardiovascular diseases. Curr Opin Cardiol 2008; 23:364-369.
29. Levy A, Yagil Y, Bursztyn M, Barkalifa R, Scharf S, Yagil C. ACE2 expression and activity are enhanced during pregnancy. Am J Physiol 2008; 295:R1953-R1961.
30. Rentzsch B, Todiras M, Iliescu R, Popova E, Campos LA, Oliveira ML, et al. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 2008; 52:967-973.
31. Coffman TM, Crowley SD. Kidney in hypertension: Guyton redux. Hypertension 2008; 51:811-816.
32. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1-7): in vivo and in vitro studies. Am J Physiol 1996; 270:F141-F147.
33. Heller J, Kramer HJ, Malý J, Cervenka L, Horác?ek V. Effect of intrarenal infusion of angiotensin-(1-7) in the dog. Kidney Blood Press Res 2000; 23:89-94.
34. Iyer SN, Averill DB, Chappel MC, Yamada K, Allred AJ, Ferrario CM. Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension 2000; 36:417-422.
35. Nakamura S, Averill DB, Chappell MC, Diz DI, Brosnihan KB, Ferrario CM. Angiotensin receptors contribute to blood pressure homeostasis in salt-depleted SHR. Am J Physiol 2003; 284:R164-R173.
36. Nakamoto H, Ferrario CM, Fuller SB, Robacyewski DL, Winicov E, Dean RH. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension 1995; 25:796-802.
37. Soler MJ, Wysocki J, Batlle D. Angiotensin-converting enzyme 2 and the kidney. Exp Physiol 2008; 93:549-556.
38. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Phillip N, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006; 116:2218-2225.
39. Hall JE, Brands MW. The renin-angiotensin-aldosterone system: renal mechanisms and circulatory homeostasis. In: Seldin DW, Giebisch G, editors. The kidney: physiology and pathophysiology. Philadelphia: Lippincott Williams & Wilkins; 2000. pp. 1009-1046.
40. Hall JE, Granger JP, Hester RL, Coleman TG, Smith MJ Jr, Cross RB. Mechanisms of escape from sodium retention during angiotensin II hypertension. Am J Physiol 1984; 246:F627-F634.
41. van den Wouden EA, Ochodnický P, van Dokkum RP, Roks AJ, Deelman LE, de Zeeuw D, et al. The role of angiotensin-(1-7) in renal vasculature of the rat. J Hypertens 2006; 24:1971-1978.
42. Botelho-Santos GA, Sampaio WO, Reudlehuber TL, Bader M, Campagnole-Santos MJ, Souza dos Santos RA. Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional resistance. Am J Physiol 2007; 292:H2485-H2490.
43. Mercure C, Yogi A, Callera CE, Aranha AB, Bader M, Ferreira AJ, et al. Angiotensin-(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008; 103:1319-1326.